Kimberly-Clark headquarters, 2019 archive: Tony Webster (CC BY-SA 2.0; crop).
Kimberly-Clark completed its acquisition of Kenvue on Monday, November 2, bringing Tylenol, Listerine and Neutrogena into the same company as Huggies and Kleenex. The closing, announced at 9:02 a.m. Eastern time, moves the combination from an agreed transaction to an operating integration.
Kenvue shareholders will receive $3.50 in cash and 0.14625 shares of Kimberly-Clark common stock for each Kenvue share they held, according to the company’s closing announcement. Kenvue shares, which traded on the New York Stock Exchange as KVUE, ceased trading as of Monday’s market opening.
For households, the deal puts a wider range of everyday medicine, skin care, baby care and paper products under one corporate owner. The combined portfolio includes 10 brands the company describes as billion-dollar brands: Huggies, Listerine, Cottonelle, Neutrogena, Depend, Tylenol, Kleenex, Johnson’s Baby, Kotex and Scott. The closing itself does not establish that retail prices or product availability have changed.
Kimberly-Clark reiterated anticipated run-rate synergies of approximately $2.1 billion. Those are projected benefits from combining the businesses, not savings already achieved at closing. The company said its integration plan includes a pipeline of cost and revenue initiatives.
The forecast comprises about $1.9 billion in cost synergies to be captured in the first three years after closing, plus about $500 million in incremental profit from revenue synergies, partly offset by about $300 million of reinvestment, within four years. The timing and delivery of those targets remain subject to integration risks.
The company will operate through four segments: North America; Asia Pacific Focus Markets; Europe, the Middle East and Africa; and Enterprise Markets. The latter includes Latin America, India, Southeast Asian markets and Japan. Kimberly-Clark said it had appointed a leadership team to manage the combined businesses.
Three former Kenvue directors have joined Kimberly-Clark’s board, which now has 13 members. Mike Hsu remains chairman and chief executive. Three Kimberly-Clark directors, Mae C. Jemison, Christa S. Quarles and Jaime A. Ramirez, stepped down effective immediately in connection with the closing.
The next test is execution rather than deal approval. In its forward-looking-statement warning, Kimberly-Clark said integration costs could exceed expectations and that anticipated benefits and savings might arrive later than expected or not at all. It also identified increased indebtedness and potential disruption to employees, customers, suppliers and operations as risks following the acquisition.
JBizNews Desk | Business
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
